Improvement in coagulation markers with antithrombin - Beneficial in severe sepsis?

Critical Care Medicine

Volumn 32, Issue 9, 2004, Pages 1968-1969

  Wiedermann, Christian J ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

Disseminated intravascular coagulation; Endogenous anticoagulant; Heparin; Peritonitis; Study design

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN; PROTEIN C;

ANTICOAGULATION; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DISEASE MARKER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; GENETIC HETEROGENEITY; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATION; LABORATORY DIAGNOSIS; LONG TERM CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS;

ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYSIS; HUMANS; SEPSIS; SERINE PROTEINASE INHIBITORS;

EID: 4444347405     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000139618.01750.86     Document Type: Editorial

References (15)

1. Taylor FB Jr: Response of anticoagulant pathways in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:619-631
2. Roemisch J, Gray E, Hoffmann JN, et al: Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13:657-670
3. Taylor FB Jr, Emerson TE Jr, Jordan R, et al: Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26:227-235
4. Niessen RW, Lamping RJ, Jansen PM, et al: Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78:1088-1092
5. Kessler CM, Tang Z, Jacobs HM, et al: The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood 1997; 89:4393-4401
6. Minnema MC, Chang AC, Jansen PM, et al: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95:1117-1123
7. Mizutani A, Okajima K, Uchiba M, et al: Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101:3029-3036
8. Fourrier F, Chopin C, Huart JJ, et al: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104:882-888
9. Baudo F, Caimi TM, de Cataldo F, et al: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-342
10. Inthorn D, Hoffmann JN, Hartl WH, et al: Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8:328-334
11. Eisele B, Lamy M, Thijs LG, et al: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672
12. Warren BL, Eid A, Singer P, et al: KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
13. Wiedermann CJ, Kaneider NC: Comparison of mechanisms after post hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. Ann Med 2004; 36:194-203
14. Hoffmann JN, Mühlbayer D, Jochum M, et al: Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004; 32:1851-1859
15. Levi M, de Jonge E, van der Poll T: New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004; 36:41-49